NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.376) was uploaded to the NHS England Website on Friday 24, October 2025.
The following changes have been introduced:
Darolutamide in combination with androgen deprivation therapy (ADT) (DARO3)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Abiraterone In combination with androgen deprivation therapy (ADT) (ABI4)
For the treatment of newly diagnosed high risk metastatic hormone-sensitive prostate cancer where the following criteria have been met
Treatment criteria (#6 and 10) updated
Apalutamide in combination with androgen deprivation therapy (ADT) (APA2)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are ineligible for chemotherapy with docetaxel where the following criteria have been met
Treatment criteria (#8 and 10) updated
Elranatamab (ELR1)
For the treatment of relapsed or refractory myeloma in adult patients who have relapsed or are refractory to their last anti-myeloma regimen AND have received at least 3 prior lines of systemic therapies which must have included at least one proteasome inhibitor, at least one immune-modulatory agent and at least one anti-CD38 antibody where the following criteria have been met
Treatment criteria (#9 and 15) updated
Enzalutamide in combination with androgen deprivation therapy (ADT) (ENZ3)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer where the following criteria have been met
Treatment criteria (#7 and 9) updated
Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy (NIV21)
For previously untreated unresectable advanced or recurrent or metastatic squamous cell carcinoma of the oesophagus with a tumour cell PD-L1 expression of 1% or more and a PD-L1 combined positive score of <10 where the following criteria have been met
Treatment criteria (#9 and 13) updated
Nivolumab with ipilimumab (NIV24)
Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Treatment criteria (#2, 9 and 11) updated
Fruquintinib (FRU1)
Fruquintinib for patients with either metastatic or locally advanced and inoperable colorectal cancer who have received 2 or more prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies with without anti-VEGF agents and/or anti- EGFR-based agents AND for whom the combination of trifluridine plus tipiracil and bevacizumab is unsuitable where the following criteria have been met
Moved into routine commissioning - section B of list
Lorlatinib monotherapy (LOR2)
Lorlatinib monotherapy for anaplastic lymphoma kinase-positive advanced non- small cell lung cancer previously untreated with an ALK inhibitor where the following criteria have been met
Date moving into routine commissioning updated